Investigation On Behalf Of Menlo Therapeutics Shareholders For Recovery Of Investment Losses

Saturday, August 11, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

BOSTON, Aug. 10, 2018 /PRNewswire/ -- Thornton Law Firm LLP is investigating a potential lawsuit on behalf of purchasers

of the securities of Menlo Therapeutics Inc. (NASDAQ: MNLO) pursuant or traceable to the registration statement and prospectus issued in connection with Menlo's January 2018 initial public offering ("IPO"). The lawsuit seeks to recover damages for Menlo
investors/shareholders under the federal securities laws. MNLO stock has dropped significantly after recent revelations that Menlo's leading product, serlopitant, is no better than a placebo at treating certain skin conditions.

If you purchased Menlo Therapeutic Inc. stock, you may have a claim for damages resulting from misstatements in the Menlo Therapeutics IPO prospectus and registration statement. To discuss your legal rights, please contact Guillaume O. Buell at the Thornton Law Firm at shareholder@tenlaw.com, or call 617-720-1333.

The investigation involves Menlo's skin-treatment drug "serlopitant" and whether Menlo has made false or misleading statements regarding the drug's success in treating pruritis associated with atopic dermatitis. In IPO materials provided to investors, including Menlo's registration statement and prospectus, Menlo may have made false and misleading statements regarding the success of serlopitant in clinical trials, the measure by which clinical data were measured, and whether serlopitant would advance to Phase 3 clinical trials or obtain FDA approval. When Menlo came clean to the market regarding the clinical failure of serlopitant, its stock dropped nearly 70%, from approximately $38/share to as low as $7/share. Investors have lost millions of dollars.

If you are a Menlo shareholder who suffered a loss, please contact Guillaume O. Buell at the Thornton Law Firm at shareholder@tenlaw.com, or call 617-720-1333.

Thornton Law Firm's securities attorneys specialize in representing individual shareholders and institutional investors in recovering damages caused by corporate fraud. Its attorneys have decades of experience litigating securities fraud cases in courts throughout the country and have a proven track record of recovering losses on behalf of shareholders. This release may be considered attorney advertising. Prior results do not guarantee any outcome.

Cision View original content:http://www.prnewswire.com/news-releases/investigation-on-behalf-of-menlo-therapeutics-shareholders-for-recovery-of-investment-losses-300695605.html

SOURCE Thornton Law Firm, LLP



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store